[1] Smit CG, Meyler L.Acute myeloid leukaemia after treatment with cytostatic agents[J]. Lancet, 1970, 2(7674):671-672.
[2] Leone G,Voso MT,Sica S, et al, Therapy related leukemias: susceptibility, prevention and treatment[J]. Leuk Lymphoma, 2001,41 (3-4): 255-276.
[3] 肖志坚,都玉书.继发性白血病的研究现况[J].中华血液学杂志,2001,22(11):613-616.
[4] Markman M. Chronic myelocytic leukemia as a secondary malignant condition in a patient receiving prolonged chemotherapy for ovarian carcinoma[J]. West J Med,1985,143 (2): 243.
[5] Atichartakarn V, Punyammalee B, Nitiyanant P. Therapy related acute non-lymphocytic leukemia: report of 4 cases[J].Southeast Asian J Trop Med Public Health,1985, 16(3):421-430.
[6] 夏忠军.卵巢癌化疗的继发性白血病[J].国际内科学杂志,1991,2(3):22-24.
[7] Chambers SK, Chopyk RL, Chambers JT, et al, Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer[J]. Cancer, 1989,64 (12): 2459-2461.
[8] Yokoyama Y, Futagami M, Fukushi Y, et al, Secondary acute nonlymphocytic leukemia following successful chemotherapy combining cisplatin, doxorubicin and cyclophosphamide for stage IV epithelial ovarian cancer[J]. Arch Gynecol Obstet,2000,263 (4): 206-207.
[9] Travis LB, Holowaty EJ, Bergfeldt K, et al, Risk of leukemia after platinum-based chemotherapy for ovarian cancer[J]. N Engl J Med, 1999,340 (5): 351-357.
[10] Yeasmin S, Nakayama K, Ishibashi M, et al, Therapy-related myelodysplasia and acute myeloid leukemia following paclitaxel-and carboplatin-based chemotherapy in an ovarian cancer patient: a case report and literature review[J]. Int J Gynecol Cancer, 2008,18 (6): 1371-1376.
[11] Ishikawa M, Nakayama K, Rahman MT, et al, Therapy-related myelodysplastic syndrome and acute myeloid leukemia following chemotherapy (paclitaxel and carboplatin) and radiation therapy in ovarian cancer: a case report[J]. Eur J Gynaecol Oncol,2014,35 (4): 443-448.
[12] Vay A, Kumar S, Seward S, et al, Therapy-related myeloid leukemia after treatment for epithelial ovarian carcinoma: an epidemiological analysis[J]. Gynecol Oncol,2011,123 (3): 456-460.